FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4255258045> ?p ?o ?g. }

• W4255258045 endingPage "1109" @default.
• W4255258045 startingPage "1097" @default.
• W4255258045 abstract "The therapeutic options for patients suffering from severe forms of spondyloarthritis (SpA) have been rather limited in recent decades. There is now accumulating evidence that anti-TNF therapy is highly effective in SpA, especially in ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Based on the data recently published on what is now several hundred AS and PsA patients, this treatment seems to be even more effective than the same therapy in rheumatoid arthritis (RA). The anti-TNF-α agents currently available, infliximab (Remicade®; Centocor), etanercept (Enbrel®; Amgen) and adalimumab (Humira™; Abbott), are approved for the treatment of RA in the US; infliximab and etanercept are approved in Europe. The situation in SpA is different to RA because there is an unmet medical need, especially in AS, since no therapies with disease-controlling antirheumatic drugs are available for severely affected patients, especially with spinal disease. Thus, TNF blockers might even be considered as first-line immunosuppressive agents in patients with active AS and PsA who are not sufficiently treated by non-steroidal anti-inflammatory drugs and sulfasalazine, if peripheral arthritis is present. For infliximab, a dosage of 5 mg/kg at intervals between 6 and 12 weeks was necessary to constantly suppress disease activity; this is also a major aim of long-term treatment. No dose-finding studies have yet been performed. The standard dose of etanercept is 25 mg s.c. twice-weekly. No studies on adalimumab (standard RA dose 20 – 40 mg s.c. every 2 weeks) have yet been conducted in SpA. The efficacy of etanercept was first demonstrated in PsA and etanercept is now approved for this indication. A double-blind study has also been performed in AS, with similarly clearcut efficacy. There is preliminary evidence that both agents do also work in other SpA such as undifferentiated SpA. Infliximab has recently been approved for short-term treatment of severe uncontrolled AS; the approval for etanercept is pending. Studies should be performed to document the long-term efficacy of this treatment. There is hope that ankylosis might be preventable but it remains to be shown whether patients benefit from long-term anti-TNF therapy and whether radiological progression and ankylosis can be stopped. Severe adverse events have remained rare. Complicated infections including tuberculosis have been reported. Tuberculosis can be mostly prevented if patients are checked for previous contact with tuberculosis. Currently, the benefits of anti-TNF therapy in AS seem to outweigh these shortcomings." @default.
• W4255258045 created "2022-05-12" @default.
• W4255258045 creator A5013787040 @default.
• W4255258045 creator A5069831361 @default.
• W4255258045 date "2003-01-01" @default.
• W4255258045 modified "2023-09-26" @default.
• W4255258045 title "Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides" @default.
• W4255258045 doi "https://doi.org/10.1517/eoid.12.7.1097.21753" @default.
• W4255258045 hasPublicationYear "2003" @default.
• W4255258045 type Work @default.
• W4255258045 citedByCount "1" @default.
• W4255258045 crossrefType "journal-article" @default.
• W4255258045 hasAuthorship W4255258045A5013787040 @default.
• W4255258045 hasAuthorship W4255258045A5069831361 @default.
• W4255258045 hasConcept C126322002 @default.
• W4255258045 hasConcept C16005928 @default.
• W4255258045 hasConcept C2776260265 @default.
• W4255258045 hasConcept C2777138892 @default.
• W4255258045 hasConcept C2777226972 @default.
• W4255258045 hasConcept C2777402515 @default.
• W4255258045 hasConcept C2777575956 @default.
• W4255258045 hasConcept C2779134260 @default.
• W4255258045 hasConcept C2779383735 @default.
• W4255258045 hasConcept C2779650986 @default.
• W4255258045 hasConcept C2780132546 @default.
• W4255258045 hasConcept C2780479503 @default.
• W4255258045 hasConcept C2780564577 @default.
• W4255258045 hasConcept C2909063479 @default.
• W4255258045 hasConcept C71924100 @default.
• W4255258045 hasConceptScore W4255258045C126322002 @default.
• W4255258045 hasConceptScore W4255258045C16005928 @default.
• W4255258045 hasConceptScore W4255258045C2776260265 @default.
• W4255258045 hasConceptScore W4255258045C2777138892 @default.
• W4255258045 hasConceptScore W4255258045C2777226972 @default.
• W4255258045 hasConceptScore W4255258045C2777402515 @default.
• W4255258045 hasConceptScore W4255258045C2777575956 @default.
• W4255258045 hasConceptScore W4255258045C2779134260 @default.
• W4255258045 hasConceptScore W4255258045C2779383735 @default.
• W4255258045 hasConceptScore W4255258045C2779650986 @default.
• W4255258045 hasConceptScore W4255258045C2780132546 @default.
• W4255258045 hasConceptScore W4255258045C2780479503 @default.
• W4255258045 hasConceptScore W4255258045C2780564577 @default.
• W4255258045 hasConceptScore W4255258045C2909063479 @default.
• W4255258045 hasConceptScore W4255258045C71924100 @default.
• W4255258045 hasIssue "7" @default.
• W4255258045 hasLocation W42552580451 @default.
• W4255258045 hasOpenAccess W4255258045 @default.
• W4255258045 hasPrimaryLocation W42552580451 @default.
• W4255258045 hasRelatedWork W129828253 @default.
• W4255258045 hasRelatedWork W1966224298 @default.
• W4255258045 hasRelatedWork W1999133482 @default.
• W4255258045 hasRelatedWork W2018484452 @default.
• W4255258045 hasRelatedWork W2082432600 @default.
• W4255258045 hasRelatedWork W2095767221 @default.
• W4255258045 hasRelatedWork W2177257388 @default.
• W4255258045 hasRelatedWork W2278536371 @default.
• W4255258045 hasRelatedWork W2408908265 @default.
• W4255258045 hasRelatedWork W2800475230 @default.
• W4255258045 hasVolume "12" @default.
• W4255258045 isParatext "false" @default.
• W4255258045 isRetracted "false" @default.
• W4255258045 workType "article" @default.